The duality of human oncoproteins: drivers of cancer and congenital disorders.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32341551.
- Also identified by DOI 10.1038/s41568-020-0256-z and PMC identifier 7787056.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Human oncoproteins promote transformation of cells into tumours by dysregulating the signalling pathways that are involved in cell growth, proliferation and death. Although oncoproteins were discovered many years ago and have been widely studied in the context of cancer, the recent use of high-throughput sequencing techniques has led to the identification of cancer-associated mutations in other conditions, including many congenital disorders. These syndromes offer an opportunity to study oncoprotein signalling and its biology in the absence of additional driver or passenger mutations, as a result of their monogenic nature. Moreover, their expression in multiple tissue lineages provides insight into the biology of the proto-oncoprotein at the physiological level, in both transformed and unaffected tissues. Given the recent paradigm shift in regard to how oncoproteins promote transformation, we review the fundamentals of genetics, signalling and pathogenesis underlying oncoprotein duality.
Medical subject headings
- Cell Transformation, Neoplastic
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Neoplasms
- Proto-Oncogene Proteins